Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Modulation of RNA splicing as a potential treatment for cancer.

Bauman JA, Kole R.

Bioeng Bugs. 2011 May-Jun;2(3):125-8. Epub 2011 May 1.

2.

Pro-apoptotic effects of splice-switching oligonucleotides targeting Bcl-x pre-mRNA in human glioma cell lines.

Li Z, Li Q, Han L, Tian N, Liang Q, Li Y, Zhao X, Du C, Tian Y.

Oncol Rep. 2016 Feb;35(2):1013-9. doi: 10.3892/or.2015.4465. Epub 2015 Nov 30.

PMID:
26718027
3.

Anti-tumor activity of splice-switching oligonucleotides.

Bauman JA, Li SD, Yang A, Huang L, Kole R.

Nucleic Acids Res. 2010 Dec;38(22):8348-56. doi: 10.1093/nar/gkq731. Epub 2010 Aug 18.

4.

Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents.

Mercatante DR, Mohler JL, Kole R.

J Biol Chem. 2002 Dec 20;277(51):49374-82. Epub 2002 Oct 14.

5.

Modification of alternative splicing of Bcl-x pre-mRNA in prostate and breast cancer cells. analysis of apoptosis and cell death.

Mercatante DR, Bortner CD, Cidlowski JA, Kole R.

J Biol Chem. 2001 May 11;276(19):16411-7. Epub 2001 Feb 7.

6.

RNA modulation, repair and remodeling by splice switching oligonucleotides.

Kole R, Williams T, Cohen L.

Acta Biochim Pol. 2004;51(2):373-8. Review.

7.

Therapeutic potential of splice-switching oligonucleotides.

Bauman J, Jearawiriyapaisarn N, Kole R.

Oligonucleotides. 2009 Mar;19(1):1-13. doi: 10.1089/oli.2008.0161. Review.

8.

Modification of alternative splicing pathways as a potential approach to chemotherapy.

Mercatante D, Kole R.

Pharmacol Ther. 2000 Mar;85(3):237-43. Review.

PMID:
10739878
9.

Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases.

Mercatante DR, Sazani P, Kole R.

Curr Cancer Drug Targets. 2001 Nov;1(3):211-30. Review.

PMID:
12188880
10.

A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells.

Zangemeister-Wittke U, Leech SH, Olie RA, Simões-Wüst AP, Gautschi O, Luedke GH, Natt F, Häner R, Martin P, Hall J, Nalin CM, Stahel RA.

Clin Cancer Res. 2000 Jun;6(6):2547-55.

11.

The importance of Bcl-xL in the survival of human RPE cells.

Zhang N, Peairs JJ, Yang P, Tyrrell J, Roberts J, Kole R, Jaffe GJ.

Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3846-53.

PMID:
17652760
12.

Switching on transgene expression by correcting aberrant splicing using multi-targeting steric-blocking oligonucleotides.

Resina S, Kole R, Travo A, Lebleu B, Thierry AR.

J Gene Med. 2007 Jun;9(6):498-510.

PMID:
17471591
13.

Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides.

Taylor JK, Zhang QQ, Wyatt JR, Dean NM.

Nat Biotechnol. 1999 Nov;17(11):1097-100.

PMID:
10545916
14.

RNA splicing manipulation: strategies to modify gene expression for a variety of therapeutic outcomes.

Wilton SD, Fletcher S.

Curr Gene Ther. 2011 Aug;11(4):259-75. Review.

PMID:
21453280
15.

Modification of alternative splicing of Bcl-x pre-mRNA in bladder cancer cells.

Zhu Z, Xing S, Cheng P, Zeng F, Lu G.

J Huazhong Univ Sci Technolog Med Sci. 2006;26(2):213-6.

PMID:
16850750
16.

Identification of a human cDNA encoding a novel Bcl-x isoform.

Ban J, Eckhart L, Weninger W, Mildner M, Tschachler E.

Biochem Biophys Res Commun. 1998 Jul 9;248(1):147-52.

PMID:
9675101
17.

Splice-switching antisense oligonucleotides as therapeutic drugs.

Havens MA, Hastings ML.

Nucleic Acids Res. 2016 Aug 19;44(14):6549-63. doi: 10.1093/nar/gkw533. Epub 2016 Jun 10. Review.

18.
19.

Heterogeneous nuclear ribonucleoprotein F/H proteins modulate the alternative splicing of the apoptotic mediator Bcl-x.

Garneau D, Revil T, Fisette JF, Chabot B.

J Biol Chem. 2005 Jun 17;280(24):22641-50. Epub 2005 Apr 18.

20.

Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product.

Smythe WR, Mohuiddin I, Ozveran M, Cao XX.

J Thorac Cardiovasc Surg. 2002 Jun;123(6):1191-8.

Supplemental Content

Support Center